World Pharma News Digest - 26.03.2012
0 views
Skip to first unread message
Ruslan David
Mar 26, 2012, 4:42:25 AM3/26/12
to worldph...@googlegroups.com
Want to place your News, Brand, Service, Product or Event in front of World Pharma News?
World Pharma News' strong, innovative capabilities can ensure you to create a compelling advertising campaign that reaches all your objectives and desired audiences. For further information, please download World Pharma News' Media Pack (.pdf, 319 KB).
Read more...
http://www.worldpharmanews.com/contact-us
World Pharma News' strong, innovative capabilities can ensure you to create a compelling advertising campaign that reaches all your objectives and desired audiences. For further information, please download World Pharma News' Media Pack (.pdf, 319 KB).
Read more...
http://www.worldpharmanews.com/contact-us
Roche's Herceptin given by subcutaneous injection offers greater convenience and reduces costs
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced results from the Phase III HannaH study in women with HER2-positive early breast cancer (eBC) showing for the first time that a new way of giving Herceptin (trastuzumab) by subcutaneous (SC) injection leads to comparable efficacy (based on pathological complete response (pCR);
Read more...
http://www.worldpharmanews.com/roche/2016-roches-herceptin-given-by-subcutaneous-injection-offers-greater-convenience-and-reduces-costs
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced results from the Phase III HannaH study in women with HER2-positive early breast cancer (eBC) showing for the first time that a new way of giving Herceptin (trastuzumab) by subcutaneous (SC) injection leads to comparable efficacy (based on pathological complete response (pCR);
Read more...
http://www.worldpharmanews.com/roche/2016-roches-herceptin-given-by-subcutaneous-injection-offers-greater-convenience-and-reduces-costs
UK court finds SEROQUEL XR® formulation patent invalid
AstraZeneca announced that the High Court in the UK has rendered its opinion on the formulation patent protecting SEROQUEL XR® (quetiapine fumarate) prolonged-release tablets currently pending in the UK court. The court found the formulation patent protecting SEROQUEL XR (marketed as SEROQUEL XL in the UK) to be invalid.
Read more...
http://www.worldpharmanews.com/astrazeneca/2015-uk-court-finds-seroquel-xrr-formulation-patent-invalid
AstraZeneca announced that the High Court in the UK has rendered its opinion on the formulation patent protecting SEROQUEL XR® (quetiapine fumarate) prolonged-release tablets currently pending in the UK court. The court found the formulation patent protecting SEROQUEL XR (marketed as SEROQUEL XL in the UK) to be invalid.
Read more...
http://www.worldpharmanews.com/astrazeneca/2015-uk-court-finds-seroquel-xrr-formulation-patent-invalid
Abbott selects AbbVie as new name for future research-based pharmaceutical company
Abbott (NYSE: ABT) announced that AbbVie [pronounced Abb-vee] will be the name of the new, independent research-based pharmaceutical company it expects to launch by the end of 2012. The naming of the new company is the latest milestone in the process that began in October 2011,
Read more...
http://www.worldpharmanews.com/abbott/2014-abbott-selects-abbvie-as-new-name-for-future-research-based-pharmaceutical-company
Abbott (NYSE: ABT) announced that AbbVie [pronounced Abb-vee] will be the name of the new, independent research-based pharmaceutical company it expects to launch by the end of 2012. The naming of the new company is the latest milestone in the process that began in October 2011,
Read more...
http://www.worldpharmanews.com/abbott/2014-abbott-selects-abbvie-as-new-name-for-future-research-based-pharmaceutical-company
Remaining TC-5214 Phase III efficacy studies do not meet endpoint
AstraZeneca and Targacept, Inc. announced top-line results from the remaining Phase III studies investigating efficacy, tolerability and safety of TC-5214 as an adjunct therapy to an antidepressant in patients with major depressive disorder (MDD) who did not respond adequately to initial antidepressant treatment.
Read more...
http://www.worldpharmanews.com/astrazeneca/2013-remaining-tc-5214-phase-iii-efficacy-studies-do-not-meet-endpoint
AstraZeneca and Targacept, Inc. announced top-line results from the remaining Phase III studies investigating efficacy, tolerability and safety of TC-5214 as an adjunct therapy to an antidepressant in patients with major depressive disorder (MDD) who did not respond adequately to initial antidepressant treatment.
Read more...
http://www.worldpharmanews.com/astrazeneca/2013-remaining-tc-5214-phase-iii-efficacy-studies-do-not-meet-endpoint
Pain relievers could be spiking your blood pressure
Diseases such as kidney failure and endocrine tumors are among the suspects causing high blood pressure - but could the common pain relievers in your medicine cabinet be the culprit?
Read more...
http://www.worldpharmanews.com/research/2012-pain-relievers-could-be-spiking-your-blood-pressure
Diseases such as kidney failure and endocrine tumors are among the suspects causing high blood pressure - but could the common pain relievers in your medicine cabinet be the culprit?
Read more...
http://www.worldpharmanews.com/research/2012-pain-relievers-could-be-spiking-your-blood-pressure
Discovery provides blueprint for new drugs that can inhibit hepatitis C virus
Chemists at the University of California, San Diego have produced the first high resolution structure of a molecule that when attached to the genetic material of the hepatitis C virus prevents it from reproducing.
Read more...
http://www.worldpharmanews.com/research/2011-discovery-provides-blueprint-for-new-drugs-that-can-inhibit-hepatitis-c-virus
Chemists at the University of California, San Diego have produced the first high resolution structure of a molecule that when attached to the genetic material of the hepatitis C virus prevents it from reproducing.
Read more...
http://www.worldpharmanews.com/research/2011-discovery-provides-blueprint-for-new-drugs-that-can-inhibit-hepatitis-c-virus
FDA approves first Boniva generics to treat or prevent osteoporosis
The U.S. Food and Drug Administration today approved the first generic versions of Boniva (ibandronate) tablets, a once-monthly product to treat or prevent osteoporosis in women after menopause.
Read more...
http://www.worldpharmanews.com/fda/2010-fda-approves-first-boniva-generics-to-treat-or-prevent-osteoporosis
The U.S. Food and Drug Administration today approved the first generic versions of Boniva (ibandronate) tablets, a once-monthly product to treat or prevent osteoporosis in women after menopause.
Read more...
http://www.worldpharmanews.com/fda/2010-fda-approves-first-boniva-generics-to-treat-or-prevent-osteoporosis
Mayo Clinic researchers building melanoma vaccine to combat skin cancer
Mayo Clinic researchers have trained mouse immune systems to eradicate skin cancer from within, using a genetic combination of human DNA from melanoma cells and a cousin of the rabies virus.
Read more...
http://www.worldpharmanews.com/research/2009-mayo-clinic-researchers-building-melanoma-vaccine-to-combat-skin-cancer
Mayo Clinic researchers have trained mouse immune systems to eradicate skin cancer from within, using a genetic combination of human DNA from melanoma cells and a cousin of the rabies virus.
Read more...
http://www.worldpharmanews.com/research/2009-mayo-clinic-researchers-building-melanoma-vaccine-to-combat-skin-cancer
PharmaNews.eu / Latest News
Somatic stem cells obtained from skin cells for first time ever
http://www.pharmanews.eu/research-and-development/1024-somatic-stem-cells-obtained-from-skin-cells-for-first-time-ever
http://www.pharmanews.eu/research-and-development/1024-somatic-stem-cells-obtained-from-skin-cells-for-first-time-ever
analytica presents biotechnology highlights
http://www.pharmanews.eu/conferences-and-events/1023-analytica-presents-biotechnology-highlights
http://www.pharmanews.eu/conferences-and-events/1023-analytica-presents-biotechnology-highlights
Study highlights risks from arm difference in blood pressure
http://www.pharmanews.eu/research-and-development/1022-study-highlights-risks-from-arm-difference-in-blood-pressure
http://www.pharmanews.eu/research-and-development/1022-study-highlights-risks-from-arm-difference-in-blood-pressure
A look back at PHARM Connect Congress 2012
http://www.pharmanews.eu/conferences-and-events/1021-a-look-back-at-pharm-connect-congress-2012
http://www.pharmanews.eu/conferences-and-events/1021-a-look-back-at-pharm-connect-congress-2012
New vaccine strategy to advance solutions for tuberculosis
http://www.pharmanews.eu/research-and-development/1020-new-vaccine-strategy-to-advance-solutions-for-tuberculosis
http://www.pharmanews.eu/research-and-development/1020-new-vaccine-strategy-to-advance-solutions-for-tuberculosis
Nanopills release drugs directly from the inside of cells
http://www.pharmanews.eu/research-and-development/1019-nanopills-release-drugs-directly-from-the-inside-of-cells
http://www.pharmanews.eu/research-and-development/1019-nanopills-release-drugs-directly-from-the-inside-of-cells
MI Health Forum to provide the healthcare system with innovative prescriptions
http://www.pharmanews.eu/conferences-and-events/1018-mi-health-forum-to-provide-the-healthcare-system-with-innovative-prescriptions
http://www.pharmanews.eu/conferences-and-events/1018-mi-health-forum-to-provide-the-healthcare-system-with-innovative-prescriptions
With best regards,
Ruslan David
Administrator/Editor
Ruslan David
Administrator/Editor
PS: Download World Pharma News' Media Pack (.pdf, 214 KB) http://www.worldpharmanews.com/images/media_pack.pdf
Reply all
Reply to author
Forward
0 new messages